CAPR (Capricor Therapeutics, Inc.) — Stock Analysis, Catalysts & AI Research

Capricor Therapeutics, Inc.

$9.40

Health CareBiotechnology

The Read: 7% on delayed FDA approval and legal disputes, then plummeted 21.

CAPR

Hover to view data

No Data

The Stats

Market Cap

N/A

Total outstanding shares value

Earnings Per Share (EPS)

N/A

Latest reported

Net Profit Margin

N/A

Net Income / Revenue

Revenue Growth (YoY)

N/A

Prior year same period

Debt / Equity

N/A

Leverage risk indicator

Dividend Yield

0.00%

Annualized Return

Free Cash Flow

N/A

No data

Capricor Therapeutics, Inc.

$9.40

Health CareBiotechnology

The Read: 7% on delayed FDA approval and legal disputes, then plummeted 21.

CAPR

Hover to view data

No Data

The Stats

Market Cap

N/A

Total outstanding shares value

Earnings Per Share (EPS)

N/A

Latest reported

Net Profit Margin

N/A

Net Income / Revenue

Revenue Growth (YoY)

N/A

Prior year same period

Debt / Equity

N/A

Leverage risk indicator

Dividend Yield

0.00%

Annualized Return

Free Cash Flow

N/A

No data

Start your free trial to unlock active Expected Moves for CAPR

Expected Moves

Capricor Therapeutics, Inc.

The Stats

Market Cap

Earnings Per Share (EPS)

Net Profit Margin

Revenue Growth (YoY)

Debt / Equity

Dividend Yield

Free Cash Flow

Start your free trial to unlock active Expected Moves for CAPR

Expected Moves

Capricor Therapeutics, Inc.

The Stats

Market Cap

Earnings Per Share (EPS)

Net Profit Margin

Revenue Growth (YoY)

Debt / Equity

Dividend Yield

Free Cash Flow